Henry Schein (HSIC) Scheduled to Post Earnings on Tuesday

Henry Schein (NASDAQ:HSIC) will be announcing its earnings results before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $1.17 per share for the quarter. Henry Schein has set its FY24 guidance at $4.70-$4.82 EPS and its FY 2024 guidance at 4.700-4.820 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.01. The company had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The firm’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm posted $1.31 earnings per share. On average, analysts expect Henry Schein to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Henry Schein Stock Up 0.2 %

Shares of Henry Schein stock opened at $70.37 on Friday. The company’s fifty day simple moving average is $70.63 and its two-hundred day simple moving average is $69.79. Henry Schein has a 12-month low of $60.01 and a 12-month high of $82.63. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46. The company has a market cap of $8.92 billion, a P/E ratio of 26.06, a PEG ratio of 2.02 and a beta of 0.87.

Analysts Set New Price Targets

A number of research firms recently issued reports on HSIC. StockNews.com downgraded shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday. Evercore ISI upped their price target on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. decreased their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Barrington Research reaffirmed an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a research report on Friday, September 20th. Finally, UBS Group decreased their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Henry Schein presently has a consensus rating of “Hold” and an average price target of $77.50.

Insider Buying and Selling at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.14% of the stock is owned by company insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.